COMPARISON OF TREATMENT STRATEGIES FOR SPACE MOTION SICKNESS

被引：19

作者：

DAVIS, JR

JENNINGS, RT

BECK, BG

机构：

[1] NASA, Lyndon B. Johnson Space Center, Houston

来源：

ACTA ASTRONAUTICA | 1993年 / 29卷 / 08期

关键词：

D O I：

10.1016/0094-5765(93)90074-7

中图分类号：

V [航空、航天];

学科分类号：

08 ; 0825 ;

摘要：

Treatment strategies for Space Motion Sickness (SMS) were compared using the results of postflight oral debriefings. Standardized questionnaires were administered to all crewmembers immediately following Space Shuttle flights by NASA flight surgeons. Cases of SMS were graded as mild, moderate, or severe based on published criteria, and medication effectiveness was judged based on subjective reports of symptom relief. Since October 1989, medication effectiveness is reported inflight through Private Medical Conferences with the crew. A symptom matrix was analyzed for 19 crewmembers treated with oral combination of scopolamine and dextroamphetamine (scopdex) and 15 crewmembers treated with promethazine delivered by intramuscular i.m. or suppository routes. Scopdex has been given preflight as prophylaxis for SMS, but analysis showed delayed symptom presentation in 9 crewmembers or failed to prevent symptoms in 7. Only 3 crewmembers who took scopdex had no symptoms inflight. Fourteen out of 15 crewmembers treated with i.m. promethazine and 6 of 8 treated with promethazine suppositories after symptom development had immediate (within 1-2 h) symptom relief and required no additional medication. There were no cases of delayed symptom presentation in the crewmembers treated with promethazine. This response is in contrast to untreated crewmembers who typically have slow symptom resolution over 72-96 h. We conclude that promethazine is an effective treatment of SMS symptoms inflight. NASA policy currently recommends treating crewmembers with SMS after symptom development, and no longer recommends prophylaxis with scopdex due to delayed symptom development and apparent variable absorption of oral medications during early flight days.

引用

页码：587 / 591

页数：5

共 15 条

[1]

Davis, Vanderploeg, Santy, Jennings, Stewart, Space motion sickness during 24 flights of the space shuttle, Aviat. Space envir. Med., 59, pp. 1185-1189, (1988)

[2]

Graybiel, Space motion sickness: Skylab revisited, Aviat. Space envir. Med., 51, pp. 814-822, (1980)

[3]

Graybiel, Lackner, Treatment of severe space motion sickness with antimotion sickness drug injections, Aviat. Space envir. Med., 58, pp. 773-776, (1987)

[4]

Matsnev, Yakovleva, Tarasov, Alekseev, Kornilova, Mateev, Gorgiladze, Space motion sickness: phenomenology, countermeasures and mechanisms, Aviat. Space envir. Med., 54, pp. 312-317, (1983)

[5]

Thronton, Moore, Pool, Vanderploeg, Clinical characterization and etiology of space motion sickness, Aviat. Space envir. Med., 58, pp. A1-A8, (1987)

[6]

Vanderploeg, Stewart, Davis, Space motion sickness, Proceedings of the 2nd International Conference on Space Physiology, pp. 137-142, (1985)

[7]

Vorobyov, Gazenko, Genin, Egorov, Medical results of Salyut-6 manned space flights, Aviat. Space envir. Med., 54, pp. S31-S40, (1983)

[8]

Wood, Manno, Manno, Redetzki, Wood, Vekovius, Side-effects of antimotion sickness drugs, Aviat. Space envir. Med., 55, 2, pp. 113-116, (1984)

[9]

Wood, Manno, Wood, Manno, Redetzki, Mechanisms of anti-motion sickness drugs, Aviat. Space envir. Med., 58, pp. A262-A265, (1987)

[10]

Biomedical Operations and Research Branch, Synopsis of promethazine clinical pharmacodynamics, (1990)

← 1 2 →